Doravirine clinical trials
Also written MK-1439 and Pifeltro.
Counted the way a researcher would: Doravirine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses doravirine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the doravirine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Aug 2018 · PIFELTRO · NDA 210806 (FDA, Drugs@FDA)
- European Union
- 22 Nov 2018 · Delstrigo · EMEA/H/C/004746 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 21
Merck Sharp & Dohme LLC (15) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (3) · Chelsea and Westminster NHS Foundation Trust (2) · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (2) · Fundacion Clinic per a la Recerca Biomédica (1) · University of North Carolina, Chapel Hill (1) · Radboud University Medical Center (1) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Lamivudine (9) · Tenofovir (8) · Islatravir (4) · Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (2) · Bictegravir, emtricitabine, tenofovir alafenamide, drug combination (1) · Spironolactone (1) · Estradiol (1) · Rifapentine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test doravirine, phase 3 first.
- Nov 2026Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy SwitchPhase 3 · Chelsea and Westminster NHS Foundation Trust
- Jan 2027Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH SuccessfullyPhase 2 · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Studies
Open first, then newest update. How each study uses doravirine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 36
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)RecruitingPhase 2Merck Sharp & Dohme LLCNCT04375800Written as Doravirine
- DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07862569Written as DOR/ISL
- Efficacy and Safety of Doravirine in the Rapid InitiationRecruitingPhase 4Fundación HuéspedNCT07357584Written as Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet
- DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionRecruitingPhase 3ANRS, Emerging Infectious DiseasesNCT06203132Written as Doravirine + tenofovir DF + lamivudine
- Doravirine Dose Optimisation in PregnancyRecruitingPhase 4University of LiverpoolNCT05630638Written as Doravirine
- Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH SuccessfullyRecruitingPhase 2Centre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaNCT06774872Written as Doravirine 100Mg Tab and Lamivudine 300 Mg Tab
- HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open LabelRecruitingPhase 2Centre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaNCT04513626Written as DORAVIRINE 100 MG [Pifeltro]
- Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTIRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT06602622Written as Doravirine + tenofovir DF + lamivudine
- Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy SwitchRecruitingPhase 3Chelsea and Westminster NHS Foundation TrustNCT04892654Written as Doravirine
- Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant WomenCompletedPhase 1University of North Carolina, Chapel HillNCT04900974Written as Doravirine
- Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding VolunteersCompletedPhase 4Radboud University Medical CenterNCT05648201Written as Doravirine 100Mg Tab
- A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)CompletedPhase 1Merck Sharp & Dohme LLCNCT07086079Written as DOR/ISL
- Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVCompletedEarly Phase 1University of Texas Southwestern Medical CenterNCT04820933Written as Doravirine 100 Mg
- Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir AlafenamideCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT04636437Written as Doravirine 100 Mg
- Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender WomenCompletedPhase 1Thomas Jefferson UniversityNCT04283656Written as Doravirine/Lamivudine/Tenofovir
- Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)CompletedPhase 2Merck Sharp & Dohme LLCNCT02652260Written as Doravirine, Tenofovir, Lamivudine - Blinded
- Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233216Written as DOR
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)CompletedPhase 3Merck Sharp & Dohme LLCNCT02403674Written as Doravirine, Tenofovir, Lamivudine
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)CompletedPhase 3Merck Sharp & Dohme LLCNCT02397096Written as Doravirine, Tenofovir, Lamivudine
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT02275780Written as Doravirine
See all 36 studies that test doravirine →
Given beside what is tested · 9 — doravirine is usual care or a partner of the new treatment
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05705349Written as DOR/ISL
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233879Written as DOR/ISL
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223791Written as DOR/ISL
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223778Written as DOR/ISL
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05766501Written as DOR/ISL
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05631093Written as DOR/ISL
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05630755Written as DOR/ISL
- A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)CompletedPhase 1Merck Sharp & Dohme LLCNCT06719570Written as Doravine
- Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)CompletedPhase 2Merck Sharp & Dohme LLCNCT04295772Written as DOR/ISL
Codes
What other systems call doravirine · ClinicalTrials.gg INT000104
- MeSH (NLM) C000592662doravirineOne source NLM
- UNII (FDA) 913P6LK81MDORAVIRINEConfirmed FDA, NLM, Wikidata
- RxNorm 2055755Confirmed FDA, Wikidata
- Wikidata Q6885419doravirineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171848DoravirineOne source FDA
- DrugBank DB12301One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592662 | doravirine | One source NLM |
| UNII (FDA) | 913P6LK81M | DORAVIRINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2055755 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6885419 | doravirine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171848 | Doravirine | One source FDA |
| DrugBank | DB12301 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.